On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year.

A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in decades has failed a pivotal test intended to support expanding its use ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

Preliminary analyses suggest that Cobenfy as an adjunctive treatment to an atypical antipsychotic was associated with improvements in symptoms of schizophrenia compared to placebo plus an atypical ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported topline outcomes from the Phase III ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported topline outcomes from the Phase III ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Bristol Myers Squibb has shared results from its Phase III ARISE trial evaluating Cobenfy (xanomeline and trospium chloride) as an add on therapy to atypical antipsychotics in adults with inadequately ...

Using a well-known, 210-point scale that measures the severity of schizophrenia symptoms, researchers found scores in the Cobenfy group improved by 14.3 points. Though that change was roughly two ...

The shocking murder of former Karnataka Police chief Om Prakash, allegedly by his wife Pallavi, has triggered widespread outrage. Pallavi was arrested following a complaint by their son, Kartikesh ...

Bris­tol My­ers Squibb’s at­tempt to turn Coben­fy in­to a megablock­buster neu­ro­science drug ran in­to a stum­bling block Tues­day af­ter­noon.

Bristol Myers Squibb Co.’s treatment for schizophrenia failed in a study designed to expand its use, denting the company’s ambitions to turn it into a blockbuster. Cobenfy, already approved to ...

Summary: The retina, as part of the central nervous system, may reflect early signs of brain disorders like schizophrenia. A large-scale genetic study found that people with higher genetic risk for ...